KAYAKU spirit是日本化药集团的应有形象（即企业愿景）。
作为实现KAYAKU spirit的企业活动有CSR（Corporate Social
Responsibility）经营。同时作为开展KAYAKU spirit的行动规范，制定了
集团行働指南、日本化药集团行为宪章•行为基准。
What's New
- 2023/10/19
- Updated information of sustainability
- 2023/10/18
- Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication
- 2023/09/25
-
Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody.
- 2022/11/16
-
Launch in Japan of Bevacizumab BS for I.V. Infusion 100mg・400mg “CTNK” ,an anti-VEGF humanized monoclonal antibody
- 2021/06/30
-
New Late-Breaking Data at The American Diabetes Association Show GlycoMark May Be an Effective Test for COVID-19 Severity
投资者关系
投资者关系资讯
